Drugs / RO7515629
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05769959 | Jun 2023 → Mar 2024 | colorectal cancer, non-small cell lung carcinoma, ovarian neoplasm, pancreatic adenocarcinoma +1 | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7515629 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05769959 ↗ |
| Route | Intravenous | “RO7515629 will be administered intravenously” NCT05769959 ↗ |